A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Matteo TruccoJulio C BarredoJohn GoldbergGilles M LeclercGregory A HaleJonathan D GillBhuvana A SettyTiffany SmithRichard LushJae K LeeDamon R ReedPublished in: Pediatric blood & cancer (2018)
The VXLD with metformin was tolerable with a RP2D for metformin of 1,000 mg/m2 /day and yielded responses in a heavily pretreated population. ER stress was induced and toxicities attributable to metformin occurred in all dose levels.